Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12653432 | 0.92 | POLB (0.50) | POLBP2RX7KMT2AALDH1A1HTT | |
| SCHEMBL31650310 | 0.83 | P2RX7 (0.46) | POLBP2RX7KMT2AALDH1A1HTT | |
| SCHEMBL31650239 | 0.82 | POLB (0.48) | POLBP2RX7KMT2AALDH1A1HTT | |
| SCHEMBL4800365 | 0.79 | SLC6A4 (0.49) | POLBP2RX7KMT2AALDH1A1SLC6A4 | |
| SCHEMBL1806218 | 0.78 | HSD11B1 (0.54) | KMT2AALDH1A1MEN1SLC6A4SLC6A3 | |
| SCHEMBL364190 | 0.78 | HSD11B1 (0.65) | POLBP2RX7KMT2AALDH1A1MEN1 | |
| SCHEMBL12886837 | 0.78 | POLB (0.52) | POLBP2RX7KMT2AMEN1SLC6A4 | |
| SCHEMBL24309995 | 0.77 | ALDH1A1 (0.44) | KMT2AALDH1A1MEN1LMNAKDM4E | |
| SCHEMBL14944333 | 0.77 | SLC6A4 (0.40) | ALDH1A1SLC6A4SLC6A3 | |
| SCHEMBL21131084 | 0.77 | SLC6A4 (0.49) | KMT2AALDH1A1MEN1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2592071-B1 | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, TBXA2R | POLB 3030/4885P2RX7 80/4885KMT2A 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.